SongT, PavelAB, WenHC, et al.An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation. J Allergy Clin Immunol, 2018; 142(5):1631–1634.e13.
2.
NezamololamaN, FieldhouseK, MetzgerK, et al.Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context, 2020; 9:2020. -8-5. doi:10.7573/dic.2020-8-5.
3.
RodriguesMA, TorresT. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat, 2020; 31(1):33–40. doi:.
4.
Magdaleno-TapialJ, Valenzuela-OñateC, García-Legaz-MartínezM, et al.Improvement of alopecia areata with dupilumab in a patient with severe atopic dermatitis and review the literature. Australas J Dermatol, 2020; 61(2):e223–e225.
5.
MontillaAM, Gómez-GarcíaF, Gómez-AriasPJ, et al.Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther (Heidelb), 2019; 9(4):655–683.
